- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 3.2 Exhibit 3.2
- 3.4 Exhibit 3.4
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.12 Exhibit 10.12
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.6 Exhibit 99.6
- EX-FILING FEES Ex-filing Fees
- 12 Jul 23 EFFECT Notice of effectiveness
- 11 Jul 23 424B3 Prospectus supplement
- 7 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 6 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 30 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 May 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 2 Feb 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 16 Dec 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
17 Oct 22 S-4 Registration of securities issued in business combination transactions
- 1 May 23 Registration of securities issued in business combination transactions (amended)
- 2 Feb 23 Registration of securities issued in business combination transactions (amended)
- 16 Dec 22 Registration of securities issued in business combination transactions (amended)
- 17 Oct 22 Registration of securities issued in business combination transactions
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement on this Form S-4 of our report dated September 28, 2022, except for Note 10 which is dated October 17, 2022 (which includes an explanatory paragraph as to the Company’s ability to continue as a going concern), with respect to our audits of the balance sheets of Estrella Biopharma, Inc. as of June 30, 2022 and June 30, 2021 (Predecessor), and the related statements of operations, changes in shareholders’ deficit, and cash flows for the period from March 30, 2022 (inception) through June 30, 2022, the period from July 1, 2021 through March 29, 2022 (Predecessor), and for the year ended June 30, 2021 (Predecessor) and related notes. We also consent to the reference to our firm under the heading “Experts” in the Prospectus.
/s/ Friedman LLP | |
New York, New York | |
October 17, 2022 |